Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins

Vaccine

Volumn 31, Issue 1, 2012, Pages 219-225

  Richards, Katherine A ^a   Chaves, Francisco A ^a   Alam, Shabnam ^a   Sant, Andrea J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

CD4+ T cell; Epitope; Immmunodominance; Immune response; Vaccine

Indexed keywords

INFLUENZA VACCINE; MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY; T LYMPHOCYTE ANTIGEN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; IMMUNITY; IMMUNOGENICITY; IMMUNOREACTIVITY; INFLUENZA; INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; VACCINES, INACTIVATED; VIRAL PROTEINS; VIRION;

EID: 84870532357     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.039     Document Type: Article

References (64)

1. Lambert L.C., Fauci A.S. Influenza vaccines for the future. N Engl J Med 2010, 363(November (21)):2036-2044.
2. Monto A.S. Seasonal influenza and vaccination coverage. Vaccine 2010, 28(September (Suppl. 4)):D33-D44.
3. Nair H., Brooks W.A., Katz M., Roca A., Berkley J.A., Madhi S.A., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011, 378(December (9807)):1917-1930.
4. Molinari N.A., Ortega-Sanchez I.R., Messonnier M.L., Thompson W.W., Wortley P.M., Weintraub E., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25(June (27)):5086-5096.
5. Kumar D., Blumberg E.A., Danziger-Isakov L., Kotton C.N., Halasa N.B., Ison M.G., et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant 2011, 11(October (10)):2020-2030.
6. McElhaney J.E. Influenza vaccine responses in older adults. Ageing Res Rev 2011, 10(July (3)):379-388.
7. Fukuyama S., Kawaoka Y. The pathogenesis of influenza virus infections: the contributions of virus and host factors. Curr Opin Immunol 2011, 23(August (4)):481-486.
8. Valkenburg S.A., Rutigliano J.A., Ellebedy A.H., Doherty P.C., Thomas P.G., Kedzierska K. Immunity to seasonal and pandemic influenza A viruses. Microbes Infect 2011, 13(May (5)):489-501.
9. Katz J.M., Veguilla V., Belser J.A., Maines T.R., Van Hoeven N., Pappas C., et al. The public health impact of avian influenza viruses. Poult Sci 2009, 88(April (4)):872-879.
10. Yen H.L., Webster R.G. Pandemic influenza as a current threat. Curr Top Microbiol Immunol 2009, 333:3-24.
11. Subbarao K., Murphy B.R., Fauci A.S. Development of effective vaccines against pandemic influenza. Immunity 2006, 24(January (1)):5-9.
12. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(January (1)):36-44.
13. Carter N.J., Curran M.P. Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 2011, 71(August (12)):1591-1622.
14. Minor P.D. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production. Clin Infect Dis 2010, 50(February (4)):560-565.
15. Schultz-Cherry S., Jones J.C. Influenza vaccines: the good, the bad, and the eggs. Adv Virus Res 2010, 77:63-84.
16. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21(May (16)):1776-1779.
17. Wood J.M., Major D., Heath A., Newman R.W., Hoschler K., Stephenson I., et al. Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard. Vaccine 2012, 30(January (2)):210-217.
18. Katz J.M., Hancock K., Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther 2011, 9(June (6)):669-683.
19. Whitmire J.K. Induction and function of virus-specific CD4+ T cell responses. Virology 2011, 411(March (2)):216-228.
20. Thomas P.G., Keating R., Hulse-Post D.J., Doherty P.C. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006, 12(January (1)):48-54.
21. McKinstry K.K., Strutt T.M., Swain S.L. Hallmarks of CD4+ T cell immunity against influenza. J Intern Med 2011, 269(May (5)):507-518.
22. Strutt T.M., McKinstry K.K., Swain S.L. Functionally diverse subsets in CD4+ T cell responses against influenza. J Clin Immunol 2009, 29(March (2)):145-150.
23. Sette A., Moutaftsi M., Moyron-Quiroz J., McCausland M.M., Davies D.H., Johnston R.J., et al. Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 2008, 28(June (6)):847-858.
24. Wirth T.C., Xue H.H., Rai D., Sabel J.T., Bair T., Harty J.T., et al. Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8(+) T cell differentiation. Immunity 2010, 33(July (1)):128-140.
25. Masopust D., Ha S.J., Vezys V., Ahmed R. Stimulation history dictates memory CD8+ T cell phenotype: implications for prime-boost vaccination. J Immunol 2006, 177(July (2)):831-839.
26. Sant A.J., Chaves F.A., Krafcik F.R., Lazarski C.A., Menges P., Richards K., et al. Immunodominance in CD4+ T-cell responses: implications for immune responses to influenza virus and for vaccine design. Expert Rev Vaccines 2007, 6(June (3)):357-368.
27. Richards K.A., Chaves F.A., Krafcik F.R., Topham D.J., Lazarski C.A., Sant A.J. Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4+ T-cell response to influenza virus hemagglutinin. J Virol 2007, 81(July (14)):7608-7619.
28. Nayak J.L., Richards K.A., Chaves F.A., Sant A.J. Analyses of the specificity of CD4+ T cells during the primary immune response to influenza virus reveals dramatic MHC-linked asymmetries in reactivity to individual viral proteins. Viral Immunol 2010, 23(April (2)):169-180.
29. Richards K.A., Chaves F.A., Sant A.J. Infection of HLA-DR1 transgenic mice with a human isolate of influenza a virus (H1N1) primes a diverse CD4+ T-cell repertoire that includes CD4+ T cells with heterosubtypic cross-reactivity to avian (H5N1) influenza virus. J Virol 2009, 83(July (13)):6566-6577.
30. Richards K.A., Chaves F.A., Sant A.J. The memory phase of the CD4+ T-cell response to influenza virus infection maintains its diverse antigen specificity. Immunology 2011, 133(June (2)):246-256.
31. Krug R.M., Etkind P.R. Cytoplasmic and nuclear virus-specific proteins in influenza virus-infected MDCK cells. Virology 1973, 56(November (1)):334-348.
32. Suarez D.L. Overview of avian influenza DIVA test strategies. Biologicals 2005, 33(December (4)):221-226.
33. Tumpey T.M., Alvarez R., Swayne D.E., Suarez D.L. Diagnostic approach for differentiating infected from vaccinated poultry on the basis of antibodies to NS1, the nonstructural protein of influenza A virus. J Clin Microbiol 2005, 43(February (2)):676-683.
34. Chaves F.A., Lee A.H., Nayak J.L., Richards K.A., Sant A.J. The utility and limitations of current Web-available algorithms to predict peptides recognized by CD4+ T cells in response to pathogen infection. J Immunol 2012, 188(May (9)):4235-4248.
35. Combadiere B., Siberil S., Duffy D. Keeping the memory of influenza viruses. Pathol Biol (Paris) 2010, 58(April (2)):e79-e86.
36. Waffarn E.E., Baumgarth N. Protective B cell responses to flu--no fluke!. J Immunol 2011, 186(April (7)):3823-3829.
37. McMurry J.A., Johansson B.E., De Groot A.S. A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A. Hum Vaccine 2008, 4(March-April (2)):148-157.
38. Kaur K., Sullivan M., Targeting Wilson P.C. B cell responses in universal influenza vaccine design. Trends Immunol 2011, 32(November (11)):524-531.
39. Epstein S.L., Price G.E. Cross-protective immunity to influenza A viruses. Expert Rev Vaccines 2010, 9(November (11)):1325-1341.
40. Hillaire M.L., Osterhaus A.D., Rimmelzwaan G.F. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol 2011, 2011:939860.
41. Fiers W., De Filette M., El Bakkouri K., Schepens B., Roose K., Schotsaert M., et al. M2e-based universal influenza A vaccine. Vaccine 2009, 27(October (45)):6280-6283.
42. Ebrahimi S.M., Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 2011, 42(February (1)):1-8.
43. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16(March (3)):265-273.
44. Steel J., Lowen A.C., Wang T.T., Yondola M., Gao Q., Haye K., et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010, (April (1)).
45. Richards K.A., Topham D., Chaves F.A., Sant A.J. Cutting edge: CD4+ T cells generated from encounter with seasonal influenza viruses and vaccines have broad protein specificity and can directly recognize naturally generated epitopes derived from the live pandemic H1N1 virus. J Immunol 2010, 185(November (9)):4998-5002.
46. Alam S., Sant A.J. Infection with seasonal influenza virus elicits CD4+ T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus. J Virol 2011, 85(December (24)):13310-13321.
47. Matthews J.T. Egg-based production of influenza vaccine: 30 years of commercial experience. Bridge 2006, 36:17-24.
48. Srinivasan A., Foley J., McSorley S.J. Massive number of antigen-specific CD4+ T cells during vaccination with live attenuated Salmonella causes interclonal competition. J Immunol 2004, 172(Junuary (11)):6884-6893.
49. Stockinger B., Barthlott T., Kassiotis G. The concept of space and competition in immune regulation. Immunology 2004, 111(March (3)):241-247.
50. Johansson B.E., Moran T.M., Bona C.A., Kilbourne E.D. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin III. Reduced generation of neuraminidase-specific helper T cells in hemagglutinin-primed mice. J Immunol 1987, 139(6):2015-2019.
51. Kedl R.M., Rees W.A., Hildeman D.A., Schaefer B., Mitchell T., Kappler J., et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 2000, 192(8):1105-1113.
52. Smith A.L., Wikstrom M.E., Fazekas de St G.B. Visualizing T cell competition for peptide/MHC complexes: a specific mechanism to minimize the effect of precursor frequency. Immunity 2000, 13(6):783-794.
53. Kastenmuller W., Gasteiger G., Gronau J.H., Baier R., Ljapoci R., Busch D.H., et al. Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med 2007, 204(September (9)):2187-2198.
54. Sarkar S., Teichgraber V., Kalia V., Polley A., Masopust D., Harrington L.E., et al. Strength of stimulus and clonal competition impact the rate of memory CD8+ T cell differentiation. J Immunol 2007, 179(November (10)):6704-6714.
55. Di Genova G., Savelyeva N., Suchacki A., Thirdborough S.M., Stevenson F.K. Bystander stimulation of activated CD4+ T cells of unrelated specificity following a booster vaccination with tetanus toxoid. Eur J Immunol 2010, 40(April (4)):976-985.
56. Kedl R.M., Rees W.A., Hildeman D.A., Schaefer B., Mitchell T., Kappler J., et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 2000, 192(October (8)):1105-1113.
57. Willis R.A., Kappler J.W., Marrack P.C. CD8+ T cell competition for dendritic cells in vivo is an early event in activation. Proc Natl Acad Sci USA 2006, 103(August (32)):12063-12068.
58. Paris R.M., Kim J.H., Robb M.L., Michael N.L. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines 2010, 9(September (9)):1055-1069.
59. Nicol M.P., Grobler L.A. MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults. Curr Opin Mol Ther 2010, 12(February (1)):124-134.
60. Hill A.V., Reyes-Sandoval A., O'Hara G., Ewer K., Lawrie A., Goodman A., et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccine 2010, 6(January (1)):78-83.
61. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009, 21(June (3)):346-351.
62. Newman M.J. Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses. Curr Opin Investig Drugs 2002, 3(March (3)):374-378.
63. Rech A.J., Vonderheide R.H. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009, 1174(September):99-106.
64. Ha S.J., West E.E., Araki K., Smith K.A., Ahmed R. Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol Rev 2008, 223(June):317-333.